Janus Henderson Group Discloses 10.6% Passive Stake In Mirum Pharmaceuticals As Of June 28
$JHG
$MIRM
Investment Managers
Finance
Biotechnology: Pharmaceutical Preparations
Health Care
- Form 13G
- Form 13G
Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 9/12/2024 | $37.00 | Equal Weight | Wells Fargo | |
| 9/9/2024 | $33.00 → $37.00 | Sell → Neutral | UBS | |
| 5/15/2024 | $34.00 → $37.00 | Hold → Buy | TD Cowen | |
| 4/17/2024 | $48.00 | Buy | Stifel | |
| 2/2/2024 | $28.00 → $31.00 | Underweight → Neutral | JP Morgan | |
| 1/5/2024 | $25.00 | Sell | UBS | |
| 1/4/2024 | $30.00 | Market Perform | TD Cowen | |
| 12/18/2023 | $60.00 → $58.00 | Buy | H.C. Wainwright |
Third quarter global net product sales of $90.3 million; 2024 guidance increased to $330 - 335 million Volixibat granted breakthrough therapy designation for treatment of cholestatic pruritus in PBC, interim results to be presented as a Late Breaker presentation at AASLD's The Liver Meeting® 2024 PDUFA date for chenodiol in CTX is December 28, 2024 In-licensed global rights to PDE4D inhibitor MRM-3379 Conference call to provide business updates today, November 12 at 5:30 a.m. PT/8:30 a.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today reported financial results for the third quarter 2024 and provided a business update. "The Mirum team executed across all aspects of the
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that it will report third quarter 2024 financial results on November 12, 2024. Mirum will also host a conference call to discuss the third quarter 2024 financial results and recent corporate progress. Conference call details: Tuesday, November 12, 2024 8:30 a.m. ET / 5:30 a.m. PT Dial-in: U.S./Toll-Free: + 1 833 470 1428 International: + 1 404 975 4839 Passcode: 749358 You may also access the call via webcast by visiting the Events & Presentations section on Mirum's website. A replay of this webcast will be available for 30 days. About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. is a biopharmaceutical company
Solid investment performance, with 75%, 71%, 67%, and 85% of assets under management ("AUM") outperforming relevant benchmarks on a one-, three-, five-, and 10-year basis, respectively, as of September 30, 2024 Consecutive quarters of net inflows with third quarter 2024 net inflows of US$0.4 billion Third quarter 2024 diluted EPS of US$0.17 includes a US$111.9 million non-cash, non-operating, accounting expense release. Adjusted diluted EPS of US$0.91 is an increase of 42% year over year AUM increased 6% quarter over quarter and 24% year over year to US$382.3 billion as of September 30, 2024 Returned US$102 million in capital to shareholders through dividends and share buybacks in
13F-HR - JANUS HENDERSON GROUP PLC (0001274173) (Filer)
10-Q - Mirum Pharmaceuticals, Inc. (0001759425) (Filer)
10-Q - JANUS HENDERSON GROUP PLC (0001274173) (Filer)
SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Tim Walbert and Paul Hoelscher, to the board of directors of the Company, effective April 1, 2024. "We are fortunate to have Tim and Paul join us at this key stage as we prepare to initiate a pivotal, Phase 3 trial for our lead candidate denifanstat in MASH in the second half of 2024," said Dave Happel, CEO of Sagimet. "With his experience as CEO of publi
Se NodThera Ltd ("NodThera" or the "Company") NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer BOSTON, MA, February 5, 2024 - NodThera, a leading clinical-stage biotech developing brain-penetrant NLRP3 inhibitors to treat chronic inflammatory diseases, today announces the appointment of Thomas Jaecklin, M.D., M.Sc., FMH as Chief Medical Officer (CMO), with effect from today. With more than 20 years of experience across global large pharma, biotech and academic medicine, Dr. Jaecklin is an accomplished late-stage drug development leader. He brings deep expertise across multiple therapy areas, including neuroscience and inflammation, with a strong track reco
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that in conjunction with the recent appointment of Joanne Quan, MD as Chief Medical Officer, the Compensation Committee of Mirum's Board of Directors approved an inducement grant of non-qualified stock options to purchase 75,000 shares of common stock and 37,500 restricted stock units ("RSUs") under Mirum's 2020 Inducement Plan. The Compensation Committee approved the awards as an inducement material to Dr. Quan's employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $26.72 per share, Mirum's closing trading price on January 16, 2024, and will vest over four years, wi
- Late-breaker presentation to feature data from VANTAGE study evaluating volixibat in primary biliary cholangitis Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that it will present data at the American Association for the Study of Liver Disease's (AASLD) The Liver Meeting®, taking place November 15-19, 2024, in San Diego, California. Enclosed below are the titles that have been accepted for presentation during the meeting. The abstracts are available via the AASLD website. Full analyses will be available following their presentation within the Publications & Presentation section on Mirum's website. Presentations Abstract #5038: Volixibat for Cholestatic Pruritus in Prim
Janus Henderson (NYSE:JHG) today announced it has launched the Janus Henderson Income ETF (Ticker: JIII). The new ETF seeks high current income with a secondary focus on capital appreciation. The Fund pursues its investment objective by primarily investing across fixed income sectors in a portfolio of US and non-US debt securities of varying maturities that the investment team believes have high relative income potential. Janus Henderson's research expertise across corporate credit, securitized credit, and emerging market debt research provides the foundation for security selection within the portfolio. The Fund is managed by Portfolio Managers John Kerschner, CFA, and John Lloyd. They
Third quarter global net product sales of $90.3 million; 2024 guidance increased to $330 - 335 million Volixibat granted breakthrough therapy designation for treatment of cholestatic pruritus in PBC, interim results to be presented as a Late Breaker presentation at AASLD's The Liver Meeting® 2024 PDUFA date for chenodiol in CTX is December 28, 2024 In-licensed global rights to PDE4D inhibitor MRM-3379 Conference call to provide business updates today, November 12 at 5:30 a.m. PT/8:30 a.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today reported financial results for the third quarter 2024 and provided a business update. "The Mirum team executed across all aspects of the
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
4 - JANUS HENDERSON GROUP PLC (0001274173) (Reporting)
SC 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
SC 13G/A - JANUS HENDERSON GROUP PLC (0001274173) (Filed by)
SC 13G/A - JANUS HENDERSON GROUP PLC (0001274173) (Filed by)
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for LIVMARLI® (maralixibat) oral solution for the treatment of cholestatic pruritus in patients with progressive familial intrahepatic cholestasis (PFIC). The expanded label includes use in PFIC patients 12 months and older as well as the higher concentration formulation of LIVMARLI evaluated in the MARCH Phase 3 study.
JP Morgan analyst Kenneth Worthington maintains Janus Henderson Group (NYSE:JHG) with a Neutral and raises the price target from $36 to $38.
- Form 13G
Wells Fargo initiated coverage of Janus Henderson Group with a rating of Equal Weight and set a new price target of $37.00
UBS upgraded Janus Henderson Group from Sell to Neutral and set a new price target of $37.00 from $33.00 previously
TD Cowen upgraded Janus Henderson Group from Hold to Buy and set a new price target of $37.00 from $34.00 previously